🇺🇸

US SEC Filing Intelligence

· daily

US Executive Officer Management Changes SEC — April 08, 2026

Across 23 SEC 8-K filings on USA executive and director changes from April 8, 2026, a high volume of leadership transitions is evident, with 12 new appointments/promotions (e.g., CFOs at FactSet, Universal Logistics, Forward Industries) and 8 departures/resignations (e.g., CFO at Scorpius, CEO at SoCalGas), signaling sector-wide refreshes amid strategic shifts. Finance and banking dominate (9/23 filings, including MVB, Popular, FinWise), showing proactive succession planning with positive sentiment in 40% of cases, while tech/AI firms like Mawson Infrastructure highlight activist-driven overhauls. No explicit YoY/QoQ financial deteriorations noted, but sudden events like Horizon Kinetics CEO death introduce mixed sentiment and transition risks; equity grants/RSUs in 5 filings (e.g., SpringBig's 12.9M CEO RSUs) indicate retention-focused capital allocation. Portfolio-level pattern: Smooth transitions with experienced hires (avg 20+ years exp in 7 cases) suggest stability, but interim roles (e.g., SoCalGas COO) flag near-term execution risks. Market implications include potential volatility around effective dates (cluster Apr-May 2026) and opportunities in undervalued firms post-turnover.

23 high priority 23 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 08, 2026

Across 23 SEC 8-K filings on USA Board Room Changes dated April 8, 2026, there is elevated C-suite turnover, with 8 CFO transitions (resignations at Scorpius, Universal; appointments at FactSet, Spectral AI, Forward Industries, Catalyst Crew, Universal successor), 7 CEO-related shifts (new agreements at SpringBig/Parks America, death at Horizon Kinetics with co-CEOs, resignations at SoCalGas, new CEOs at Mawson/Navient/FinWise), and multiple director resignations (Byrna, OFA Group, Patriot National, USCB). Sentiment skews neutral (12/23) with positive tones on experienced hires and smooth successions (8 positive), mixed only at Horizon due to sudden loss of founder-CEO. No explicit YoY/QoQ financial trends or insider buys/sells reported, but equity-heavy comp packages (e.g., SpringBig CEO 12.9M RSUs, Spectral 150K options) and Change-in-Control protections signal retention amid M&A risks/opportunities. Financial sector dominates (9/23 filings: MVB, FactSet, Horizon, Universal, Patriot, Popular, Navient, FinWise, USCB) with planned transitions enhancing stability, while sudden events (Horizon death, SoCalGas CEO exit) raise interim leadership risks. Portfolio implication: Monitor finance/banking for execution continuity; leadership upgrades in tech/biotech (FactSet, Spectral, Mawson) offer relative outperformance potential vs. laggards with voids.

23 high priority 23 total filings
· daily

US Merger & Acquisition SEC Filings — April 08, 2026

The 7 filings underscore a vibrant SPAC and M&A landscape on April 8, 2026, dominated by routine post-IPO unit separation announcements in 4 blank check companies (Abony, Averin, Metals II, and contextually similar), signaling increased liquidity and readiness for business combinations in defense tech, health/tech, and metals sectors. Key outliers include Air Lease Corp's takeover completion by Sumisho (rename and capital restructure), DMAA's positive $1B non-binding LOI with Power Analytics Global Corp for de-SPAC (min $25-50M cash, potential PIPE), and Eureka Acquisition Corp's dual negative developments: a $150k working capital promissory note and delisting notice effective April 6. Sentiment is neutral across 5/7 filings, positive for DMAA (high materiality 9/10), and negative for Eureka delisting (9/10 materiality), with no explicit period-over-period financial trends but clear forward-looking catalysts like unit separations April 10-14 and LOI progression. No insider trading or capital allocation shifts beyond Air Lease's stock reclassification and preferred series designations noted; transaction details highlight undervalued SPAC targets ($750M-$1.5B for Abony) vs DMAA's $1B valuation. Portfolio-level pattern: SPAC maturation post-IPO accelerates M&A potential, but delisting risks underscore selection discipline. Implications: Bullish for de-SPAC hunters in targeted sectors, bearish caution on distressed SPACs like Eureka.

7 high priority 7 total filings
· monthly

US Pre-Market SEC Filings Roundup — April 08, 2026

Overnight SEC filings reveal a mix of robust operational performances in energy/REITs (e.g., Venture Global +177% YoY revenue, Kimco 96.4% occupancy) contrasted by biotech cash burn and revenue declines (Nurix -66% YoY revenue, cash -71% QoQ), with 50 filings dominated by neutral 13F-HR snapshots showing heavy ETF/tech allocations amid institutional positioning. Aggregate period trends show 4/7 key financial reporters with YoY revenue growth averaging +50% (ATRenew +28.9%, Grown Rogue +22%), but margins mixed due to cost inflation (Nurix op ex +21%, SmartKem op loss widened); capital returns strong via dividends/buybacks (Kimco +4% div, 6.1M shares repurchased). M&A catalysts accelerate with FTC clearances (Day One tender, CECO-Thermon HSR done), IPO expansions (Legence +2.7M shares), and SPAC updates (PlusAI/Churchill). Positive sentiment in 6/50 filings highlights shareholder returns and growth, while mixed/negative in biotechs flag liquidity risks. Portfolio implications favor energy/REIT longs, biotech shorts, with May proxy season as key volatility driver.

19 high priority 31 medium 50 total filings
· daily

Biotech Small-Cap Approvals — April 07, 2026

The FDA recorded 2 'Other' approvals in the Biotech Small-Cap stream from April 07, 2026 to April 07, 2026 (0 NMEs, 0 biosimilars, 0 label expansions), both neutral signals (5/10 strength and materiality). DEXCEL and APOTEX each gained FDA approval for biosimilar NINTEDANIB ESYLATE on 2026-04-02, enabling small-cap entrants into the nintedanib market originally dominated by Boehringer Ingelheim's Ofev. No dominant therapeutic area theme emerges, as details like indication and market sizing remain NOT_DISCLOSED. The highest-conviction signal is the NINTEDANIB ESYLATE biosimilar approvals for DEXCEL and APOTEX, offering neutral commercial entry potential with limited disclosed upside. Key risk/watch item is competitive erosion to Boehringer Ingelheim's originator franchise (30-60% revenue risk over 2-3 years).

2 total filings
· daily

Big Pharma Approvals — April 07, 2026

The FDA approval period from April 07, 2026 to April 07, 2026 featured 0 NMEs, 0 biosimilars, 0 label expansions, and 1 Other approval in the Big Pharma stream. Regeneron Pharmaceuticals secured a bullish label expansion for Aflibercept (Eylea HD), providing a moderate commercial signal with strength and materiality rated 5/10. No dominant therapeutic area theme is evident from this single event. The highest-conviction signal is Regeneron’s Aflibercept label expansion, which reinforces sponsor execution in an established franchise. Key risk/watch item: lack of disclosed peak sales, exclusivity, pricing, or market position data warrants monitoring for post-approval commercial uptake.

1 total filings
· daily

New Drug Approvals (Original) — April 07, 2026

The FDA recorded 2 Other approvals from April 07, 2026 to April 07, 2026, comprising 0 NMEs, 0 biosimilars, 0 label expansions, and 2 neutral signals. Both approvals on 2026-04-02 were fallback biosimilar approvals for NINTEDANIB ESYLATE to DEXCEL and APOTEX, signaling generic competition entry without specified therapeutic area clustering. No dominant therapeutic area theme emerges, as both involve the same molecule. The highest-conviction signal is NINTEDANIB ESYLATE biosimilar approvals to DEXCEL and APOTEX, offering neutral (5/10 strength/materiality) market entry upside for entrants but bearish erosion risk for the originator. Key risk/watch item is competitive launches by DEXCEL and APOTEX, potentially driving 30-60% originator revenue decline over 2-3 years.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — April 07, 2026

The single contract analyzed represents a $144,045,451 total obligation in federal construction and infrastructure, with a 0/1 defense-related split indicating fully civilian exposure via the Department of Health and Human Services (HHS). Hensel Phelps Construction Co secured a firm fixed price delivery order from the National Institutes of Health (NIH) for the Poolesville A&B conversion design-build project, providing multi-year revenue visibility through December 2028 (potential February 2029). This bullish signal (strength 6/10, materiality 7/10) underscores committed funding with $30,620,007 already outlayed shortly after the September 2024 start. The dominant theme is NIH institutional building construction under full and open competition. A key risk is high pricing risk inherent to the firm fixed price structure. Investors should watch outlay progress beyond the current $30.6M and performance milestones.

1 total filings
· daily

New Federal Contractors — April 07, 2026

These five new federal contracts totaling $992,695,384 in obligations represent exclusively civilian agency awards (0/5 defense-related), highlighting robust spending in IT systems design, telecommunications, voice communication infrastructure, construction, and space R&D across GSA, Treasury/IRS, DOT/FAA, HHS/NIH, and NASA. The dominant theme is multi-year civilian IT and infrastructure modernization, with Peraton Enterprise Solutions LLC's $346.8M GSA delivery order emerging as the highest-conviction bullish signal due to its scale, low pricing risk, and potential expansion to $563M. All signals are bullish with average strength of 6.4/10, led by high-materiality wins for Peraton, Rohde & Schwarz USA Inc ($167.6M FAA), and Verizon ($264.6M IRS). A key risk is execution dependency, as three contracts (Peraton, Rohde & Schwarz, Hensel Phelps) show limited or zero outlays despite large obligations, vulnerable to delays in future performance periods extending to 2028-2032. Investors should watch option exercises and outlay ramps for revenue realization.

5 total filings
· daily

Significant Contract Modifications ($10M+) — April 07, 2026

These five significant civilian contract modifications, totaling $992,695,384 in obligations with 0/5 defense-related, highlight bullish signals in civilian IT, telecom, construction, and space R&D across GSA, Treasury/IRS, DOT/FAA, HHS/NIH, and NASA. Dominant theme is sustained civilian agency investments in enterprise IT support and infrastructure, led by Peraton Enterprise Solutions LLC's highest-materiality $346.8M GSA delivery order for computer systems design. Highest-conviction signal is Peraton's low-risk cost-plus award fee structure with up to $563M potential, providing multi-year revenue visibility. Verizon's $264.6M IRS telecom transition shows strong execution with $209M outlayed. Key risk is execution dependency on firm-fixed price contracts like Rohde & Schwarz USA Inc.'s $167.6M FAA voice systems (high pricing risk, $0 outlayed, future March 2026 start).

5 total filings
· daily

Contract Deobligations Alert — April 07, 2026

Five civilian agency contracts totaling $992,695,384 in obligations highlight steady demand for IT systems design, telecommunications, aviation voice systems, construction, and space R&D, with zero defense-related awards. Dominant themes include GSA/FAA-led IT/telecom infrastructure and HHS/NASA project-specific spending. Highest-conviction bullish signal is Peraton Enterprise Solutions LLC's $346.8M GSA delivery order for computer systems design, offering low-risk cost-plus structure and up to $563M potential. Verizon Business Network Services LLC's $264.6M IRS telecom transition adds multi-year visibility with $209M already outlayed. Key risk is execution dependency, as Peraton, Rohde & Schwarz USA Inc ($167.6M FAA), and others show $0 outlays to date amid firm fixed-price exposures.

5 total filings
· daily

Contract Option Exercises — April 07, 2026

These five contract option exercises total $992,695,384 in obligations, with 0/5 defense-related and all tied to civilian agencies including GSA, Treasury/IRS, DOT/FAA, HHS/NIH, and NASA. Dominant themes include civilian IT systems design, telecommunications transitions, voice communication infrastructure, building construction, and space R&D, signaling steady non-defense federal spending. Highest-conviction bullish signal is Peraton Enterprise Solutions LLC's $346.8M GSA FEDSIM delivery order for computer systems design, offering low-risk cost-plus revenue through 2026-2027 amid $0 outlays to date. Verizon Business Network Services LLC's $264.6M IRS telecom order shows strong execution with $209M already outlayed. Key watch item is outlay progress across contracts, as three have $0-$30M outlayed despite large obligations, introducing execution dependency.

5 total filings
· daily

Federal IT & Cybersecurity Contracts — April 07, 2026

Peraton Enterprise Solutions LLC secured the sole contract in this digest, a $346,769,435 obligated delivery order from GSA's FEDSIM office for computer systems design services, representing 100% civilian exposure with 0/1 defense-related awards. This full and open competition win under a cost-plus award fee structure signals strong positioning in GSA civilian IT support, with potential upside to $562,995,039 including options through 2027. The highest-conviction bullish signal is the low financial risk and multi-year revenue visibility for Peraton, estimating $87M-$113M annually. A key watch item is total outlay progress from the current $0, as execution dependency and high subcontracting ($357M across 369 subs) could delay revenue realization.

1 total filings
· daily

NASA & Space Contracts Intelligence — April 07, 2026

NASA awarded Lockheed Martin Corp a $69,721,101 firm fixed price contract for the Tipping Point Cryogenic Demonstration Mission, representing the sole obligation in this NASA & Space Contracts Intelligence stream with a 0/1 defense-related split, fully civilian-focused. The contract, managed by NASA Marshall Space Flight Center under full and open competition (NAICS 541715, PSC AR13), underscores Lockheed's space R&D expertise with $62,721,101 already outlayed and 157 subawards totaling $27,812,346. The highest-conviction signal is bullish for Lockheed Martin, signaling steady revenue through 2026 amid space technology priorities. A key watch item is the remaining $7M outlay and performance completion by 2026-04-03, coupled with high pricing risk under firm fixed price terms.

1 total filings
· daily

All HHS Contracts — April 07, 2026

HHS obligated $144,045,451 across 1 contract during the April 07, 2026 period, with 0% defense-related and 100% civilian allocation to NIH construction projects. The dominant theme is institutional building conversion at NIH's Poolesville facility, led by a single high-materiality award to Hensel Phelps Construction Co. The highest-conviction bullish signal is multi-year revenue visibility from the fully funded $144M firm fixed price delivery order, with $30.6M already outlayed signaling early execution. Key watch item is outlay progress beyond $30.6M and performance toward the December 20, 2028 end date (potential February 9, 2029), amid high pricing risk from the firm fixed price structure.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — April 07, 2026

Four mega contracts totaling $922,974,283 in obligations, all awarded to civilian agencies (0/4 defense-related), highlight robust federal IT, telecom, and construction spending across GSA, Treasury/IRS, DOT/FAA, and HHS/NIH. Peraton Enterprise Solutions LLC's $346.8M GSA IT delivery order and Rohde & Schwarz USA Inc.'s $167.6M FAA voice communication systems award represent the highest-conviction bullish signals due to their top materiality scores (8/10) and multi-year revenue potential up to $563M and $250M respectively including options. Verizon Business Network Services LLC's $264.6M IRS telecom transition and Hensel Phelps Construction Co's $144M NIH building conversion add diversified civilian exposure with partial outlays already at $209.4M and $30.6M. Key risk: zero outlays on Peraton and Rohde & Schwarz contracts signal execution dependency ahead of revenue recognition.

4 total filings
· daily

High-Value Federal Grants ($5M+) — April 07, 2026

These five high-value civilian federal contracts total $992,695,384 in obligations, with 0/5 defense-related, highlighting robust spending across GSA, Treasury/IRS, DOT/FAA, HHS/NIH, and NASA. Dominant themes include IT systems design, telecommunications transitions, voice communication infrastructure, building construction, and space R&D, all awarded via full and open competition to non-small businesses. Highest-conviction bullish signal is Peraton Enterprise Solutions LLC's $346.8M GSA delivery order for computer systems design, offering low-risk cost-plus structure and up to $563M potential. Verizon Business Network Services LLC's $264.6M IRS telecom order shows strong execution with $209M outlayed. Key risk is execution dependency, as three contracts (Peraton, Rohde & Schwarz USA Inc., Hensel Phelps) have minimal or zero outlays despite large obligations, alongside high firm-fixed-price risks in Rohde ($167.6M FAA), Hensel Phelps ($144M NIH), and Lockheed Martin ($69.7M NASA).

5 total filings
· daily

General Federal Contracts — April 07, 2026

These five civilian contracts totaling $992,695,384 in obligations represent strong bullish signals for institutional investors eyeing non-defense government services exposure, with zero defense-related awards across GSA, Treasury/IRS, DOT/FAA, HHS/NIH, and NASA. Dominant themes include multi-year IT systems design, telecommunications transitions, and infrastructure construction, led by Peraton Enterprise Solutions LLC's highest-materiality $346.8M GSA award for computer systems design services. Highest-conviction signal is Peraton's cost-plus structure reducing execution risk over a 4-5 year horizon with up to $563M potential. Key risk is zero outlays to date on the two largest contracts (Peraton and Rohde & Schwarz), signaling future revenue dependency on execution milestones.

5 total filings
· daily

All NASA Contracts — April 07, 2026

NASA awarded a single $69,721,101 firm fixed price contract to Lockheed Martin Corp for the Tipping Point Cryogenic Demonstration Mission, representing 100% civilian obligations with zero defense-related activity during the April 07, 2026 period. This full and open competition win under NAICS 541715 for space R&D services aligns with Lockheed Martin's space expertise, with $62,721,101 already outlayed and 157 subawards totaling $27,812,346. The highest-conviction bullish signal is validation of Lockheed Martin's competitive position in NASA space R&D, contributing an estimated $14.9M annual revenue through 2026-04-03. A key watch item is the remaining $7M outlays and performance completion by 2026-04-03, amid high contract pricing risk due to firm fixed price terms.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 07, 2026

Across the 10 filings in the USA S&P 500 Technology intelligence stream, governance and proxy-related disclosures dominate (5/10 filings), highlighting heightened shareholder activism and board defenses amid sector pressures. Period-over-period trends are sparse but stark in Aditxt's acquisition of Ignite Proteomics, where net losses widened 154% YoY to $5.7M, revenues plunged 40% to $43.5k, assets dropped 76% to $257k, and liabilities tripled to $7.1M, raising integration risks. Leadership transitions show stability with PSQ's seamless CFO handover and QumulusAI's stabilized exec team post-multiple changes, contrasting Aditxt's troubled M&A. Mixed sentiments prevail (e.g., Genco's proxy battle rejecting $23.50/share takeover), with neutral routine updates in CDCC, FHLB bonds, and bank filings; overall, low sector-wide growth signals but opportunities in IPO prep (QumulusAI) and financial structure shifts (Chemung). Critical implications include monitoring May 2026 AGMs for voting outcomes and takeover escalations, as capital allocation remains defensive with no dividend/buyback accelerations noted. Portfolio-level pattern: 40% of filings flag governance catalysts, potentially driving volatility in tech-adjacent names.

3 high priority 7 medium 10 total filings